At a glance
ClinicalIndex Comparison RecordPhase 2Active· 43 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NEO-SPACE Trial: Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin Followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for NPC. Active but no longer recruiting, targeting 43 participants across 2 sites in 2 countries.
Detailed Summary
This is an open label, single arm, non-randomized, multi-site, phase 2 clinical trial of neoadjuvant pembrolizumab in combination with gemcitabine-cisplatin for 2 cycles,followed by concurrent pembrolizumab-cisplain-radiation, and then maintainence pembrolizumab monotherpy given every 3 weeks for a total treatment duration of 12 months, in previously untreated stage IVA ( UICC 8 th Edition ) nasopharyngeal cancer(NPC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNPC
CountriesHong Kong, Singapore
Collaborators--
Timeline
Phase 2Active
2019202020212022202320242025202620272028
First PostedNov 2018
Enrollment StartMay 2019
Primary CompletionJan 2025
TodayJul 2026
Study CompletionDec 2027
First PostedNov 8, 2018
Enrollment StartMay 3, 2019
Primary CompletionJan 25, 2025
Study CompletionDec 31, 2027
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 7.6 years ago
Interventions
Pembrolizumabdrug
200mg every 3 weeks infusion